Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
CNY 29.1
(-2.68%)
CNY 29.1
(-2.68%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -658.17 Million CNY | -117.89% |
| 2022 | 3.68 Billion CNY | -36.29% |
| 2021 | 5.77 Billion CNY | 192.57% |
| 2020 | 1.97 Billion CNY | 2068.81% |
| 2019 | 91.03 Million CNY | 21.12% |
| 2018 | 75.15 Million CNY | 101.93% |
| 2017 | 37.21 Million CNY | -7.69% |
| 2016 | 40.31 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -146.65 Million CNY | 62.15% |
| 2024 Q3 | -122.76 Million CNY | 16.17% |
| 2024 Q2 | -146.43 Million CNY | 0.15% |
| 2023 Q2 | 62.17 Million CNY | 227.61% |
| 2023 FY | -658.17 Million CNY | -117.89% |
| 2023 Q1 | -48.72 Million CNY | 95.83% |
| 2023 Q3 | -105.16 Million CNY | -269.14% |
| 2023 Q4 | -387.46 Million CNY | -268.42% |
| 2022 Q2 | 782.76 Million CNY | -68.82% |
| 2022 FY | 3.68 Billion CNY | -36.29% |
| 2022 Q4 | -1.16 Billion CNY | -390.42% |
| 2022 Q3 | 401.84 Million CNY | -48.66% |
| 2022 Q1 | 2.51 Billion CNY | 116.37% |
| 2021 Q1 | 1.37 Billion CNY | 14.62% |
| 2021 Q3 | 620.68 Million CNY | -76.29% |
| 2021 FY | 5.77 Billion CNY | 192.57% |
| 2021 Q4 | 1.16 Billion CNY | 86.95% |
| 2021 Q2 | 2.61 Billion CNY | 90.07% |
| 2020 Q3 | 166.83 Million CNY | -69.79% |
| 2020 Q1 | 53.54 Million CNY | 108.89% |
| 2020 FY | 1.97 Billion CNY | 2068.81% |
| 2020 Q4 | 1.2 Billion CNY | 620.3% |
| 2020 Q2 | 552.22 Million CNY | 931.38% |
| 2019 Q3 | 28.08 Million CNY | 11.13% |
| 2019 FY | 91.03 Million CNY | 21.12% |
| 2019 Q4 | 25.63 Million CNY | -8.73% |
| 2019 Q2 | 25.27 Million CNY | 109.74% |
| 2019 Q1 | 12.04 Million CNY | -39.2% |
| 2018 Q4 | 19.81 Million CNY | 0.0% |
| 2018 FY | 75.15 Million CNY | 101.93% |
| 2017 FY | 37.21 Million CNY | -7.69% |
| 2016 FY | 40.31 Million CNY | 0.0% |